Board of Directors
Julian Aleksov
Chairman of the Board since 2023
Julian has more than 25 years of experience in finance and international business development within the pharmaceutical and technology industries including Oasmia Pharmaceutical AB. Julian is an entrepreneur who ran his own companies for many years in several different business areas, primarily pharmaceutical development. Is an active investor and through companies also a major owner in a number of listed companies.
Number of shares: –
Education: Economist
Other assignments: Board member of Maida Vale Capital AB and Hunterhex AB.
Independent in relation to the company and its management but not to major shareholders.
Anders Blom
Board member since 2021
Anders has more than 25 years of experience within international finance and business development in the pharmaceutical– and medical device industries. His experience includes Business- and Corporate Development from Pharmacia & Upjohn, Q-Med AB (publ), partner and CEO at venture capital firm Nexttobe AB and Executive VP and CFO at Oasmia Pharmaceutical AB (publ). In addition, Anders has extensive board experience from pharma- and tech sectors including, but not limited to, Hansa Biopharma AB (publ), Biolamina AB, Delta Projects AB, Selego AB.
Number of shares *): 6,747,686 shares through Maida Vale Capital AB
Education: BSc in Business Administration and Economics at Uppsala University
Ongoing assignments: Chairman of the board of Maida Vale Capital AB, Terranet AB, Rosland Nordic AB, Black T Quant AB and board member of Hunterhex International Inc, Hunterhex AB, Evolutience Pharmaceutical AB, Wonderboo AB, Emotra AB and Challengehop Inc.
Independent in relation to the company and its management but not to major shareholders.
Per-Göran Gillberg
Board member since 2020
Per-Göran has 35 years of experience from the pharmaceutical industry. He has extensive experience in pharmacology and neuro-pharmacology from Kabi, Kabi Pharmacia, Pharmacia & Upjohn and Pharmacia, AstraZeneca and Albireo. Per-Göran is the founder of Albireo AB and was VP Development for Albireo Pharma Inc and its subsidiary Albireo AB and is affiliated with the Division of Translational Alzheimer Neurobiology, Karolinska Institute, Stockholm.
Number of shares *): 19,500 shares
Education: MSc in Chemistry, PhD in Medical Science, Adjunct Professor of Neuroscience at Uppsala University
Ongoing assignments: Board member of Dicot AB, Co-opted to the Center for Alzheimer Research at Karolinska Institute
Independent in relation to both the company and its management as well as to major shareholders.
Clas Malmeström
Board member since 2015
Clas is a physician at the Neurology clinic and at the laboratory for clinical immunology at Sahlgrenska University Hospital in Gothenburg. Since 2001 he has conducted research within Multiple Sclerosis (MS) at the hospital’s Multiple sclerosis centre and the Department of Clinical Neuroscience, University of Gothenburg. In addition to academic research, he has participated in several clinical drug trials in MS led by Biogen-Idec, Merck, Novartis, Roche and Sanofi, several of which resulted in today’s standard treatments for MS.
Number of shares *): 12,000 shares
Education: MD and PhD in Medicine, Senior consultant in Neurology and Clinical Immunology
Other assignments: –
Independent in relation to both the company and its management as well as to major shareholders.
Carol Routledge
Board member since 2018
Carol is an R&D and pharmaceutical development expert with more than 30 years of experience in UK and US-based pharmaceutical and biotechnology companies focusing on drug acquisition and profiling of NCE biology. She has played a key role in GSK Biopharmaceuticals, including management in pharmaceutical research and development activities in several therapeutic areas, especially in the areas of immuno-inflammatory diseases and neuroscience with an emphasis on translational medicine. She recently managed a semi-philanthropic dementia fund with a central focus on identifying and developing new disease-modified mechanisms for the treatment of all different types of dementia. She has over 90 articles published in scientific journals. Until recently Carol was the Director of Research and Managing Director of EDoN, a global early detection initiative at Alzheimer’s Research UK. She has since taken on the role of Chief Medical and Scientific Officer at Small Pharma, a biotech developing treatments for mental health disorders.
Number of shares: –
Education: BSc, PhD in Neuro Pharmacology
Ongoing assignments: –
Independent in relation to both the company and its management as well as to major shareholders.
Anders Waas
Board member since 2018
Anders has held several senior roles in Astra, AstraZeneca, CV Therapeutics, Actogenics and Tikomed AB. He has previous experience in management, business development, financing and pharmaceutical development.
Number of shares: –
Education: Trained dentist (DDS)
Ongoing assignments: Chairman of the of Sobrera Pharma AB and SiMSen Diagnostics AB. Board member of Nexo Therapeutics, Transmed Gothenburg AB, Xandrax AB, CerInvent AB, Nexo Therapeutics AB and Anders Waas AB.
Independent in relation to both the company and its management and dependent of major shareholders.
Lena Degling Wikingsson
Board member since 2020
Lena has 25 years of experience from the pharmaceutical industry. She has extensive experience in regulatory affairs and development of biological drugs and vaccines from Dilafor, Avaris AB, Independent Pharmaceutica AB, SBL Vaccines, Accuro Immunology and the Swedish Medical Products Agency. Lena is currently CEO of Dilafor AB.
Number of shares: –
Education: MSc in Pharmacy, PhD in pharmaceutical science
Ongoing assignments: Chairman of the board in Simplexia AB, and Dilafor Incentive AB. Board member of XNK Therapeutics AB.
Independent in relation to both the company and its management as well as to major shareholders.
*) Includes own holdings, holdings by closely associated persons and controlled companies or holdings in capital insurance accounts.